JPS6137734A - 発育不全状態及び特に小児の発育遅延の治療方法 - Google Patents

発育不全状態及び特に小児の発育遅延の治療方法

Info

Publication number: JPS6137734A
Authority: JP; Japan
Prior art keywords: arginine; administration; nanosomic; therapy; state
Prior art date: 1984-07-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP24431884A

Other languages

English (en)

Japanese (ja)

Inventor

マリー―エレーヌ・クリユゼ

アンリ・ポンタニエ

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Cortial SA

Original Assignee

Cortial SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-07-24

Filing date

1984-11-19

Publication date

1986-02-22

1984-11-19 Application filed by Cortial SA filed Critical Cortial SA

1986-02-22 Publication of JPS6137734A publication Critical patent/JPS6137734A/ja

Status Pending legal-status Critical Current

Links

208000012766 Growth delay Diseases 0.000 title 1
238000002560 therapeutic procedure Methods 0.000 title 1
SUUWYOYAXFUOLX-ZBRNBAAYSA-N (2s)-2-aminobutanedioic acid;(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CCCN=C(N)N SUUWYOYAXFUOLX-ZBRNBAAYSA-N 0.000 claims description 17
229960002223 arginine aspartate Drugs 0.000 claims description 17
206010053759 Growth retardation Diseases 0.000 claims description 6
231100000001 growth retardation Toxicity 0.000 claims description 6
238000011282 treatment Methods 0.000 claims description 6
238000000034 method Methods 0.000 claims description 3
208000037824 growth disorder Diseases 0.000 claims description 2
230000036435 stunted growth Effects 0.000 claims description 2
241000700159 Rattus Species 0.000 description 10
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
230000028327 secretion Effects 0.000 description 9
102000018997 Growth Hormone Human genes 0.000 description 8
108010051696 Growth Hormone Proteins 0.000 description 8
101710144202 Probable soluble pyridine nucleotide transhydrogenase Proteins 0.000 description 7
102100028023 Saitohin Human genes 0.000 description 7
101710165942 Soluble pyridine nucleotide transhydrogenase Proteins 0.000 description 7
239000000122 growth hormone Substances 0.000 description 7
239000004475 Arginine Substances 0.000 description 6
229960003121 arginine Drugs 0.000 description 6
102000004877 Insulin Human genes 0.000 description 5
108090001061 Insulin Proteins 0.000 description 5
235000009697 arginine Nutrition 0.000 description 5
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
230000012010 growth Effects 0.000 description 5
229940125396 insulin Drugs 0.000 description 5
102000051325 Glucagon Human genes 0.000 description 4
108060003199 Glucagon Proteins 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
230000000694 effects Effects 0.000 description 4
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 4
229960004666 glucagon Drugs 0.000 description 4
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
230000037396 body weight Effects 0.000 description 3
230000007812 deficiency Effects 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
239000005556 hormone Substances 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
210000002381 plasma Anatomy 0.000 description 3
241000282472 Canis lupus familiaris Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
230000001195 anabolic effect Effects 0.000 description 2
229940009098 aspartate Drugs 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
150000003839 salts Chemical group 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
NGZUCVGMNQGGNA-UHFFFAOYSA-N 7-[5-(2-acetamidoethyl)-2-hydroxyphenyl]-3,5,6,8-tetrahydroxy-9,10-dioxoanthracene-1,2-dicarboxylic acid 7-[5-(2-amino-2-carboxyethyl)-2-hydroxyphenyl]-3,5,6,8-tetrahydroxy-9,10-dioxoanthracene-1,2-dicarboxylic acid 3,5,6,8-tetrahydroxy-7-[2-hydroxy-5-(2-hydroxyethyl)phenyl]-9,10-dioxoanthracene-1,2-dicarboxylic acid 3,6,8-trihydroxy-1-methyl-9,10-dioxoanthracene-2-carboxylic acid Chemical compound Cc1c(C(O)=O)c(O)cc2C(=O)c3cc(O)cc(O)c3C(=O)c12.OCCc1ccc(O)c(c1)-c1c(O)c(O)c2C(=O)c3cc(O)c(C(O)=O)c(C(O)=O)c3C(=O)c2c1O.CC(=O)NCCc1ccc(O)c(c1)-c1c(O)c(O)c2C(=O)c3cc(O)c(C(O)=O)c(C(O)=O)c3C(=O)c2c1O.NC(Cc1ccc(O)c(c1)-c1c(O)c(O)c2C(=O)c3cc(O)c(C(O)=O)c(C(O)=O)c3C(=O)c2c1O)C(O)=O NGZUCVGMNQGGNA-UHFFFAOYSA-N 0.000 description 1
235000006693 Cassia laevigata Nutrition 0.000 description 1
CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
229930064664 L-arginine Natural products 0.000 description 1
235000014852 L-arginine Nutrition 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
231100000229 OECD 452 Chronic Toxicity Study Toxicity 0.000 description 1
208000007913 Pituitary Neoplasms Diseases 0.000 description 1
201000005746 Pituitary adenoma Diseases 0.000 description 1
206010061538 Pituitary tumour benign Diseases 0.000 description 1
206010039424 Salivary hypersecretion Diseases 0.000 description 1
241000735631 Senna pendula Species 0.000 description 1
208000008630 Sialorrhea Diseases 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229960005261 aspartic acid Drugs 0.000 description 1
206010003549 asthenia Diseases 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
230000008468 bone growth Effects 0.000 description 1
210000000845 cartilage Anatomy 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
231100000020 developmental retardation Toxicity 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000000459 effect on growth Effects 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
231100000225 lethality Toxicity 0.000 description 1
210000005229 liver cell Anatomy 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000017066 negative regulation of growth Effects 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000008807 pathological lesion Effects 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
208000021310 pituitary gland adenoma Diseases 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
229940124513 senna glycoside Drugs 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
241000894007 species Species 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
231100000456 subacute toxicity Toxicity 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

JP24431884A 1984-07-24 1984-11-19 発育不全状態及び特に小児の発育遅延の治療方法 Pending JPS6137734A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR8411835		1984-07-24
FR8411835A FR2568124B1 (fr)	1984-07-24	1984-07-24	Medicament pour traiter les etats hypotrophiques par administrations d'aspartate d'arginine

Publications (1)

Publication Number	Publication Date
JPS6137734A true JPS6137734A (ja)	1986-02-22

Family

ID=9306499

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP24431884A Pending JPS6137734A (ja)	1984-07-24	1984-11-19	発育不全状態及び特に小児の発育遅延の治療方法

Country Status (14)

Country	Link
JP (1)	JPS6137734A (fr)
AU (1)	AU574811B2 (fr)
BE (1)	BE902954A (fr)
CH (1)	CH660689A5 (fr)
DE (1)	DE3439805C2 (fr)
DZ (1)	DZ699A1 (fr)
FR (1)	FR2568124B1 (fr)
IT (1)	IT1177368B (fr)
LU (1)	LU86020A1 (fr)
MA (1)	MA20290A1 (fr)
NL (1)	NL8502100A (fr)
OA (1)	OA07878A (fr)
PT (1)	PT79617A (fr)
ZA (1)	ZA851683B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5019558A (en) *	1988-05-09	1991-05-28	Georges Cehovic	Method for treating memory disturbances using arginine aspartate
DE19705233A1 (de) *	1997-02-12	1998-08-13	Froelich Juergen C	Verfahren zur Herstellung einer Formulierung enthaltend Arginin

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5714530A (en) *	1980-06-30	1982-01-25	Baldacci Lab Spa	Pharmaceutic composition useful for treatment and diagnosis and feed regulant

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR106F (fr) *	1964-12-21
FR2547501A1 (fr) *	1983-06-15	1984-12-21	Opochimiotherapie Lab	Excipient effervescent, sans alcalino-terreux, contenant des composes carbonates de l'arginine et un acide, et comprimes effervescents correspondants

1984
- 1984-07-24 FR FR8411835A patent/FR2568124B1/fr not_active Expired
- 1984-10-31 DE DE3439805A patent/DE3439805C2/de not_active Expired - Lifetime
- 1984-11-10 DZ DZ847325A patent/DZ699A1/fr active
- 1984-11-19 JP JP24431884A patent/JPS6137734A/ja active Pending
- 1984-11-23 CH CH5615/84A patent/CH660689A5/fr not_active IP Right Cessation
- 1984-11-27 OA OA58455A patent/OA07878A/fr unknown
- 1984-11-29 IT IT23800/84A patent/IT1177368B/it active
- 1984-12-03 MA MA20514A patent/MA20290A1/fr unknown
- 1984-12-05 PT PT79617A patent/PT79617A/pt unknown
1985
- 1985-03-06 ZA ZA851683A patent/ZA851683B/xx unknown
- 1985-07-22 BE BE0/215391A patent/BE902954A/fr not_active IP Right Cessation
- 1985-07-22 NL NL8502100A patent/NL8502100A/nl not_active Application Discontinuation
- 1985-07-23 AU AU45273/85A patent/AU574811B2/en not_active Expired
- 1985-07-24 LU LU86020A patent/LU86020A1/fr unknown

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5714530A (en) *	1980-06-30	1982-01-25	Baldacci Lab Spa	Pharmaceutic composition useful for treatment and diagnosis and feed regulant

Also Published As

Publication number	Publication date
PT79617A (en)	1985-01-01
FR2568124A1 (fr)	1986-01-31
IT8423800A1 (it)	1986-05-29
NL8502100A (nl)	1986-02-17
DE3439805A1 (de)	1986-02-06
DE3439805C2 (de)	1994-01-20
BE902954A (fr)	1986-01-22
FR2568124B1 (fr)	1988-12-09
LU86020A1 (fr)	1986-02-12
DZ699A1 (fr)	2004-09-13
MA20290A1 (fr)	1985-07-01
AU574811B2 (en)	1988-07-14
ZA851683B (en)	1986-01-29
CH660689A5 (fr)	1987-06-15
AU4527385A (en)	1986-01-30
IT1177368B (it)	1987-08-26
OA07878A (fr)	1986-11-20
IT8423800A0 (it)	1984-11-29

Publication	Publication Date	Title
Welle et al.	1994	Postprandial myofibrillar and whole body protein synthesis in young and old human subjects
Saito et al.	1987	Metabolic and immune effects of dietary arginine supplementation after burn
US4438144A (en)	1984-03-20	Amino acid preparation and therapy for treatment of stress and injury
CA2069413A1 (fr)	1991-05-23	Methode de reduction de la cholesterolemie a l'aide de l'arginine
JP2014065740A (ja)	2014-04-17	高齢者の骨格筋量減少を防止又は改善するためのアミノ酸含有組成物
RU2697480C2 (ru)	2019-08-14	Применение режима краткосрочного голодания в сочетании с ингибиторами киназ для усовершенствования традиционной химио-лекарственной эффективности и пригодности и обращения вспять побочных эффектов от киназ в нормальных клетках и тканях
US9238024B2 (en)	2016-01-19	Methods for improving health in canines
Merimsky et al.	1990	Interferon-related mental deterioration and behavioral changes in patients with renal cell carcinoma
Jeevanandam et al.	1995	Adjuvant recombinant human growth hormone normalizes plasma amino acids in parenterally fed trauma patients
JPH01216924A (ja)	1989-08-30	肝障害治療剤
Becks et al.	1943	Comparative study of oral changes in dogs due to deficiencies of pantothenic acid, nicotinic acid, and unknowns of the B vitamin complex
JP3105541B2 (ja)	2000-11-06	慢性肝疾患治療剤
BRPI1011103B1 (pt)	2021-04-13	Composição para tratar infertilidade masculina e usos de ácido d-aspártico e de ácido l- aspártico
Lavietes et al.	1964	Thyroid therapy of myxedema: A comparison of various agents with a note on the composition of thyroid secretion in man
JP2573976B2 (ja)	1997-01-22	低カロリ−状態での窒素保持のための成長ホルモンの使用
De Vries et al.	1948	Studies on amino acid metabolism. II. Blood glycine and total amino acids in various pathological conditions, with observations on the effects of intravenously administered glycine
JPH0340010B2 (fr)	1991-06-17
Berman et al.	2019	Inhibition of dermal fibrosis by interferons
PEDEN et al.	1957	Anabolic effect of a new synthetic steroid on nitrogen metabolism after operation
JPH10114665A (ja)	1998-05-06	津液改善剤及びそれを含有する経口投与用組成物
Spencer et al.	1963	Effect of lysine on calcium metabolism in man
WO1982000411A1 (en)	1982-02-18	Novel amino acid preparation and therapy for treatment of stress and injury
Dickerson et al.	1990	Effect of propranolol on nitrogen and energy metabolism in sepsis
JP2006517588A (ja)	2006-07-27	甲状腺機能低下症を治療する方法
JP2007505892A (ja)	2007-03-15	向上した成長障害の処置方法